GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, ...

Pembrolizumab biosimilar is under clinical development by Formycon and currently in Phase III for Non-Small Cell Lung Cancer.

Lenvatinib plus pembrolizumab did not improve PFS or OS over chemotherapy in patients with advanced or recurrent endometrial ...

Potential practice-changing therapies in gynecologic cancer include the emergence of carboplatin, paclitaxel, and PD-1 ...

The following is a summary of “Neoadjuvant Pembrolizumab in Stage I-III Deficient Mismatch Repair Colon Cancer: A Clinical ...

The past 12 months have seen the FDA approvals of enfortumab vedotin plus pembrolizumab for patients with locally advanced or ...

James “Jimmy” Carter, the 39th President of the United States, passed away last week on December 29, after 22 months in Hospice care.  At | Cancer ...

PD-1 x VEGF antibodies show potential to surpass checkpoint inhibitors as standard-of-care in multiple oncology indications• NAYA aiming to ...

When Carter was diagnosed with metastatic melanoma, he told the country he'd be trying a new cutting-edge cancer treatment - immunotherapy.

The following is a summary of “A potential inflammatory biomarker for advanced endometrial cancer treated with lenvatinib ...

Leap Therapeutics focuses on developing DKN-01, a promising monoclonal antibody for solid tumors, with encouraging early ...

The SU2C-SARC032 study demonstrated that pembrolizumab combined with radiotherapy and surgery was well tolerated, with ...